Intellectual Property partner Gregory B. Sephton, special counsel Christine Willgoos and associate John P. Dillon's article "BPCIA Questions Continue To Arise For Biosimilar Applicants" appeared in Law360 on July 24, 2017. The article examines the Supreme Court's decision in Sandoz Inc. v. Amgen Inc., the first case under the Biologics Price Competition and Innovation Act of 2009.

Read the full article here.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.